SPRO
Spero Therapeutics, Inc.Company with tickers: SPRO
CIK
1701108
CUSIP
84833T103
Shares Outstanding
57,901,493
13F Activity (30d)
45 filings
45 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $5,874,000 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Revenue (ASC 606) | $12,000 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $20,605,000 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Research & Development | $13,606,000 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Operating Income | $-14,731,000 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| Net Income | $-13,866,000 | USD | 2025-03-31 | 10-Q | 2026-05-13 |
| EPS (Basic) | $-0.25 | USD/shares | 2025-03-31 | 10-Q | 2026-05-13 |
| EPS (Diluted) | $-0.25 | USD/shares | 2025-03-31 | 10-Q | 2026-05-13 |